Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors
Highlights
Predicting Hidden Risk
Nodal negativity does not equate to a cure; over 10% of patients with lymph node-negative (LN-negative) pancreatic neuroendocrine tumors (PanNETs) experience recurrence within ten years.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.